Appel ouvert en continu pour deux ans

The recent outbreak of Ebola virus disease (EVD) in West Africa underscores the vulnerability of populations worldwide to pathogens such as filoviral viruses. Currently, there are no vaccines or antiviral drugs approved for prevention or treatment of filoviral infections in humans.

Scope:

This Call provides an opportunity to capture emerging scientific advances and to progress those rapidly into health care interventions. Proposals may address aspects of pre-clinical development and/or Phase 1, 2, and 3 clinical developments of vaccines (in particular multivalent), treatments and diagnosis of Ebola or other filovirus infections. Manufacturing strategies, vaccine stability during transport and storage, and/or deployment of vaccines and treatments are also in scope. Proposals for the development of adaptable platforms, which in addition to filoviruses can address multiple other priority pathogens, are also eligible.

Soumission des projets via le portail SOFIA.

La soumission des projets se fait en une étape.

Cet appel est ouvert en continu pour 2 ans avec plusieurs dates limite de soumission (cut-off dates) :

• 16 mars 2016,
• 15 septembre 2016,
• 16 mars 2017,
• 14 septembre 2017,
• 15 mars 2018.